BMS 181339: Clinical Trials

13 trials of BMS 181339, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 9 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 29Completed 9
Phase 13Completed 3
Phase 31Completed 1

Follow BMS 181339: new trials by email Literature Review of BMS 181339 trials Research Report on BMS 181339

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
Paclitaxel, Carboplatin, Ipilimumab - Lung Cancer (NSCLC)
Phase 3CompletedBristol-Myers Squibb3422014-10-132019-08-28
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
BMS-754807, Paclitaxel, Carboplatin - Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1CompletedBristol-Myers Squibb212009-04-012012-07-13
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
Ipilimumab, Carboplatin, Paclitaxel - Advanced Melanoma
Phase 1CompletedBristol-Myers Squibb722009-02-012014-01-06
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6) - Advanced/Metastatic Non-Small Cell Lung Cancer
Phase 2CompletedR-Pharm2602008-12-012020-10-28
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
Paclitaxel - Esophageal Cancer
Phase 2CompletedBristol-Myers Squibb12008-03-012013-07-26
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg - Metastatic Breast Cancer
Phase 2CompletedR-Pharm1362007-03-012016-03-10
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
Paclitaxel - Head and Neck Cancer
Phase 2CompletedBristol-Myers Squibb112006-08-042022-04-08
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy
Alvespimycin, Trastuzumab, Paclitaxel - Solid Tumor, Breast Cancer
Phase 1CompletedBristol-Myers Squibb292006-01-012011-06-27
Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer
Paclitaxel - Head and Neck Cancer
Phase 2CompletedBristol-Myers Squibb362005-10-012010-02-04
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced Breast Cancer
Paclitaxel - Breast Cancer
Phase 2CompletedBristol-Myers Squibb62005-06-302021-05-25
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer
Paclitaxel - Head and Neck Cancer
Phase 2CompletedBristol-Myers Squibb362004-01-012011-04-25
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
Paclitaxel - Non-Small Cell Lung Cancer
Phase 2CompletedBristol-Myers Squibb602002-12-012011-04-25
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
Paclitaxel - Breast Cancer
Phase 2CompletedBristol-Myers Squibb682002-10-012010-02-04

Conditions studied

Breast Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Head and Neck Neoplasms (3)  ·  Esophageal Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasms (1)

Sponsors

Bristol-Myers Squibb (11)  ·  R-Pharm (2)

Countries

United States (4)  ·  South Korea (3)  ·  Australia (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Spain (2)  ·  Argentina (1)  ·  Canada (1)  ·  China (1)  ·  Hungary (1)  ·  Poland (1)  ·  Russia (1)  ·  Singapore (1)

Results publications

PMID 23589560

NIH funding

2014 (1)